|
Video: What is a Stock Split?
|
|
Liquidia is a biopharmaceutical company focused on the development, manufacturing and commercialization of products with focus directed towards the treatment of pulmonary hypertension (PH). Co. conducts research and manufacturing of products by applying its proprietary PRINT® technology, a particle engineering platform. Co.'s products and candidates for PH include: YUTREPIATM (treprostinil) Inhalation Powder to Treat PAH, which is an inhaled dry powder formulation of treprostinil; and Treprostinil Injection, a Generic Version of Remodulin®, which contains the same active ingredient, same strength, same dosage forms and same inactive ingredient amounts as Remodulin®. According to our Liquidia stock split history records, Liquidia has had 0 splits. | |
|
Liquidia (LQDA) has 0 splits in our Liquidia stock split history database.
Looking at the Liquidia stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Liquidia shares, starting with a $10,000 purchase of LQDA, presented on a split-history-adjusted basis factoring in the complete Liquidia stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/27/2018 |
|
End date: |
04/30/2024 |
|
Start price/share: |
$10.99 |
|
End price/share: |
$12.85 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
16.92% |
|
Average Annual Total Return: |
2.75% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$11,692.70 |
|
Years: |
5.76 |
|
|
|
|
|